PortfoliosLab logoPortfoliosLab logo
GNTA vs. NTLA
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

GNTA vs. NTLA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Genenta Science S.p.A. (GNTA) and Intellia Therapeutics, Inc. (NTLA). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, GNTA achieves a 0.67% return, which is significantly lower than NTLA's 58.12% return.


GNTA

1D
-5.66%
1M
-19.79%
6M
5.63%
YTD
0.67%
1Y
-62.13%
3Y*
-36.25%
5Y*
10Y*

NTLA

1D
-7.93%
1M
17.38%
6M
36.95%
YTD
58.12%
1Y
23.23%
3Y*
-31.12%
5Y*
-37.83%
10Y*
-3.20%
*Multi-year figures are annualized to reflect compound growth (CAGR)

GNTA vs. NTLA - Yearly Performance Comparison


2026 (YTD)20252024202320222021
GNTA
Genenta Science S.p.A.
0.67%-65.75%-12.12%-10.00%-49.82%9.07%
NTLA
Intellia Therapeutics, Inc.
58.12%-22.90%-61.76%-12.61%-70.49%2.58%

Correlation

The correlation between GNTA and NTLA is 0.10, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.10

Correlation (3Y)
Calculated over the trailing 3-year period

0.06

Correlation (All Time)
Calculated using the full available price history since Dec 15, 2021

0.06

Fundamentals

Market Cap

GNTA:

$28.72M

NTLA:

$1.60B

EPS

GNTA:

-€0.73

NTLA:

-$3.51

PB Ratio

GNTA:

1.28

NTLA:

2.71

Total Revenue (TTM)

GNTA:

€0.00

NTLA:

$66.09M

Gross Profit (TTM)

GNTA:

-€14.04K

NTLA:

-$33.92M

EBITDA (TTM)

GNTA:

-€16.27M

NTLA:

-$299.32M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

GNTA vs. NTLA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GNTA
GNTA Risk / Return Rank: 3030
Overall Rank
GNTA Sharpe Ratio Rank: 2828
Sharpe Ratio Rank
GNTA Sortino Ratio Rank: 3939
Sortino Ratio Rank
GNTA Omega Ratio Rank: 3939
Omega Ratio Rank
GNTA Calmar Ratio Rank: 1919
Calmar Ratio Rank
GNTA Martin Ratio Rank: 2626
Martin Ratio Rank

NTLA
NTLA Risk / Return Rank: 5454
Overall Rank
NTLA Sharpe Ratio Rank: 5252
Sharpe Ratio Rank
NTLA Sortino Ratio Rank: 5858
Sortino Ratio Rank
NTLA Omega Ratio Rank: 6060
Omega Ratio Rank
NTLA Calmar Ratio Rank: 5151
Calmar Ratio Rank
NTLA Martin Ratio Rank: 5050
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GNTA vs. NTLA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Genenta Science S.p.A. (GNTA) and Intellia Therapeutics, Inc. (NTLA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


GNTANTLADifference
Sharpe ratioReturn per unit of total volatility

-0.56

Sortino ratioReturn per unit of downside risk

-0.80

Omega ratioGain probability vs. loss probability

1.02

1.14

-0.11

Calmar ratioReturn relative to maximum drawdown

-0.68

0.24

-0.92

Martin ratioReturn relative to average drawdown

-0.92

0.36

-1.28

GNTA vs. NTLA - Sharpe Ratio Comparison

The current GNTA Sharpe Ratio is -0.39, which is lower than the NTLA Sharpe Ratio of 0.17. The chart below compares the historical Sharpe Ratios of GNTA and NTLA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

GNTA vs. NTLA - Drawdown Comparison

The maximum GNTA drawdown since its inception was -95.11%, roughly equal to the maximum NTLA drawdown of -96.45%. Use the drawdown chart below to compare losses from any high point for GNTA and NTLA.


Loading charts...

Drawdown Indicators


GNTANTLADifference

Max Drawdown

Largest peak-to-trough decline

-95.11%

-96.45%

+1.34%

Max Drawdown (1Y)

Largest decline over 1 year

-90.65%

-71.27%

-19.38%

Max Drawdown (3Y)

Largest decline over 3 years

-91.62%

-86.23%

-5.39%

Max Drawdown (5Y)

Largest decline over 5 years

-96.45%

Max Drawdown (10Y)

Largest decline over 10 years

-96.45%

Current Drawdown

Current decline from peak

-87.36%

-91.96%

+4.60%

Average Drawdown

Average peak-to-trough decline

-61.44%

-57.35%

-4.09%

Ulcer Index

Depth and duration of drawdowns from previous peaks

66.98%

47.20%

+19.78%

Volatility

GNTA vs. NTLA - Volatility Comparison

Genenta Science S.p.A. (GNTA) and Intellia Therapeutics, Inc. (NTLA) have volatilities of 28.11% and 27.41%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


GNTANTLADifference

Volatility (1M)

Calculated over the trailing 1-month period

28.11%

27.41%

+0.70%

Volatility (6M)

Calculated over the trailing 6-month period

95.05%

59.31%

+35.74%

Volatility (1Y)

Calculated over the trailing 1-year period

159.30%

98.49%

+60.81%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

102.52%

77.90%

+24.62%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

102.52%

78.78%

+23.74%

Dividends

GNTA vs. NTLA - Dividend Comparison

Neither GNTA nor NTLA has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

GNTA vs. NTLA - Financials Comparison

This section allows you to compare key financial metrics between Genenta Science S.p.A. and Intellia Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


-5.00M0.005.00M10.00M15.00M20.00M25.00M30.00MJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober20260
15.05M
(GNTA) Total Revenue
(NTLA) Total Revenue
Please note, different currencies. GNTA values in EUR, NTLA values in USD

Frequently Asked Questions


GNTA and NTLA have a correlation of 0.10, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

GNTA has higher volatility (28.11%) compared to NTLA (27.41%). In terms of maximum drawdown, GNTA dropped -95.11% vs NTLA's -96.45%.

NTLA currently has the higher Sharpe Ratio (0.17 vs -0.39), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for GNTA and NTLA

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer